8-KEarnings & ResultsExhibits & Filings

ABBOTT LABORATORIES 8-K Report, Financial Results (Jan 28, 2016)

Filed January 28, 2016For Securities:ABT

Summary

Abbott Laboratories (ABT) filed an 8-K on January 28, 2016, to report its financial results for the fourth quarter and full year 2015. The filing primarily references a press release (Exhibit 99.1) that details these results, with a focus on the company's use of non-GAAP financial measures to present a clearer view of ongoing operational performance. Investors should note that these non-GAAP figures adjust for significant one-time or unusual items, such as cost reduction initiatives, transaction-related costs, tax adjustments, and gains/losses on asset sales or contingent considerations. The company's management emphasizes that these non-GAAP measures, which exclude specified items and intangible amortization expense, are used internally to assess performance and are provided to investors to offer greater visibility into the underlying business operations. While useful for understanding performance trends, Abbott cautions investors to consider these non-GAAP measures alongside, and not as a substitute for, its GAAP-reported financial results. The filing itself is largely procedural, serving to incorporate the detailed financial announcement made via the press release.

Key Highlights

  • 1Abbott Laboratories announced its Q4 and full-year 2015 financial results on January 28, 2016.
  • 2The 8-K filing incorporates by reference a press release (Exhibit 99.1) containing the detailed financial results.
  • 3The company utilized non-GAAP financial measures to report earnings, excluding items like cost reduction initiatives, transaction costs, and tax adjustments.
  • 4Non-GAAP measures also excluded intangible amortization expense for enhanced visibility into ongoing business performance.
  • 5Management uses these non-GAAP figures internally to monitor business performance.
  • 6Abbott advises investors to consider non-GAAP measures in addition to, and not as a substitute for, GAAP financial measures.
  • 7The filing's primary purpose was to report these results and introduce the supplemental non-GAAP information.

Frequently Asked Questions

The main purpose of this 8-K filing is to officially report Abbott Laboratories' financial results for the fourth quarter and the full fiscal year 2015. It also serves to introduce and incorporate by reference the press release that contains the detailed financial announcements and the company's commentary on its performance.

Abbott Laboratories uses non-GAAP financial measures to provide investors with a clearer view of its ongoing operational performance. These measures exclude items that are considered unusual, unpredictable, or not indicative of core business operations, such as restructuring costs, acquisition-related expenses, and certain tax impacts. Management believes this offers better insight into how the business is performing.

Abbott's non-GAAP earnings exclude several categories of items. These include cost reduction initiatives, transaction-related costs, tax expenses from one-time events like repatriating foreign earnings, resolutions of tax uncertainties, gains on the sale of investments (such as Mylan stock mentioned in the filing), and changes in the fair value of contingent consideration from acquisitions. Intangible amortization expense is also excluded.

No, investors should not rely solely on the non-GAAP financial measures. Abbott Laboratories explicitly cautions investors to consider these non-GAAP measures in addition to, and not as a substitute for, the financial measures prepared in accordance with Generally Accepted Accounting Principles (GAAP). GAAP figures provide the standard, audited financial picture.